These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 25977400)

  • 1. Non-susceptibility to ceftaroline in healthcare-associated multiresistant MRSA in Eastern Australia.
    Mubarak N; Sandaradura I; Isaia L; O'Sullivan M; Zhou F; Marriott D; Iredell JR; Harkness J; Andresen D
    J Antimicrob Chemother; 2015 Aug; 70(8):2413-4. PubMed ID: 25977400
    [No Abstract]   [Full Text] [Related]  

  • 2. Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model.
    Zhanel GG; Rossnagel E; Nichol K; Cox L; Karlowsky JA; Zelenitsky S; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2011 Jun; 66(6):1301-5. PubMed ID: 21429940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterisation of methicillin-resistant Staphylococcus aureus with reduced susceptibility to ceftaroline collected in Russia during 2010-2014.
    Gostev V; Kalinogorskaya O; Kruglov A; Lobzin Y; Sidorenko S
    J Glob Antimicrob Resist; 2018 Mar; 12():21-23. PubMed ID: 29196221
    [No Abstract]   [Full Text] [Related]  

  • 4. A multicentre study of meticillin-resistant Staphylococcus aureus in acute bacterial skin and skin-structure infections in China: susceptibility to ceftaroline and molecular epidemiology.
    Zhang H; Xiao M; Kong F; O'Sullivan MV; Mao LL; Zhao HR; Zhao Y; Wang H; Xu YC
    Int J Antimicrob Agents; 2015 Apr; 45(4):347-50. PubMed ID: 25649348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial susceptibility patterns of community- and hospital-acquired methicillin-resistant Staphylococcus aureus from United States Hospitals: results from the AWARE Ceftaroline Surveillance Program (2012-2014).
    Sader HS; Mendes RE; Jones RN; Flamm RK
    Diagn Microbiol Infect Dis; 2016 Sep; 86(1):76-9. PubMed ID: 27394637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing epidemiology of meticillin-resistant S. aureus in Queensland, Australia, 2000-2006: use of passive surveillance of susceptibility phenotypes.
    Nimmo GR; Fong J; Paterson DL; McLaws ML
    J Hosp Infect; 2008 Dec; 70(4):305-13. PubMed ID: 18783847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Australian Staphylococcus aureus Sepsis Outcome Programme annual report, 2013.
    Coombs GW; Nimmo GR; Daly DA; Le TT; Pearson JC; Tan HL; Robinson JO; Collignon PJ; McLaws ML; Turnidge JD;
    Commun Dis Intell Q Rep; 2014 Dec; 38(4):E309-19. PubMed ID: 25631593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of ceftaroline against community associated and healthcare associated methicillin resistant Staphylococcus aureus.
    Coombs GW; Pearson JC; Robinson JO; Christiansen KJ
    Pathology; 2014 Jan; 46(1):71-3. PubMed ID: 24300719
    [No Abstract]   [Full Text] [Related]  

  • 9. Reduced In Vitro Activity of Ceftaroline by Etest among Clonal Complex 239 Methicillin-Resistant Staphylococcus aureus Clinical Strains from Australia.
    Abbott IJ; Jenney AW; Jeremiah CJ; Mirčeta M; Kandiah JP; Holt DC; Tong SY; Spelman DW
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7837-41. PubMed ID: 26392488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Australian Group on Antimicrobial Resistance Hospital-onset Staphylococcus aureus Surveillance Programme annual report, 2011.
    Coombs GW; Nimmo GR; Pearson JC; Collignon PJ; Bell JM; McLaws ML; Christiansen KJ; Turnidge JD;
    Commun Dis Intell Q Rep; 2013 Sep; 37(3):E210-8. PubMed ID: 24890956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro bactericidal activity of ceftobiprole against hospital- and community-associated methicillin-resistant Staphylococcus aureus.
    Borbone S; Campanile F; Bongiorno D; Stefani S
    J Antimicrob Chemother; 2010 Mar; 65(3):591-4. PubMed ID: 20083552
    [No Abstract]   [Full Text] [Related]  

  • 12. In vivo emergence of ceftaroline resistance during therapy for MRSA vertebral osteomyelitis.
    Sanchez EH; Mendes RE; Sader HS; Allison GM
    J Antimicrob Chemother; 2016 Jun; 71(6):1736-8. PubMed ID: 26861570
    [No Abstract]   [Full Text] [Related]  

  • 13. Missense mutations in PBP2A Affecting ceftaroline susceptibility detected in epidemic hospital-acquired methicillin-resistant Staphylococcus aureus clonotypes ST228 and ST247 in Western Switzerland archived since 1998.
    Kelley WL; Jousselin A; Barras C; Lelong E; Renzoni A
    Antimicrob Agents Chemother; 2015 Apr; 59(4):1922-30. PubMed ID: 25583724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline.
    Mendes RE; Tsakris A; Sader HS; Jones RN; Biek D; McGhee P; Appelbaum PC; Kosowska-Shick K
    J Antimicrob Chemother; 2012 Jun; 67(6):1321-4. PubMed ID: 22398650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 12-year survey of methicillin-resistant Staphylococcus aureus infections in Greece: ST80-IV epidemic?
    Drougka E; Foka A; Liakopoulos A; Doudoulakakis A; Jelastopulu E; Chini V; Spiliopoulou A; Levidiotou S; Panagea T; Vogiatzi A; Lebessi E; Petinaki E; Spiliopoulou I
    Clin Microbiol Infect; 2014 Nov; 20(11):O796-803. PubMed ID: 24750462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of methicillin-resistant Staphylococcus aureus and its antibiotic susceptibility pattern in a tertiary care hospital.
    Tiwari S; Sahu M; Rautaraya B; Karuna T; Mishra SR; Bhattacharya S
    J Indian Med Assoc; 2011 Nov; 109(11):800-1. PubMed ID: 22666934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular analysis and susceptibility patterns of methicillin-resistant Staphylococcus aureus strains causing community- and health care-associated infections in the northern region of Palestine.
    Adwan K; Jarrar N; Abu-Hijleh A; Adwan G; Awwad E; Salameh Y
    Am J Infect Control; 2013 Mar; 41(3):195-8. PubMed ID: 22998783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ST2249-MRSA-III: a second major recombinant methicillin-resistant Staphylococcus aureus clone causing healthcare infection in the 1970s.
    Nimmo GR; Steen JA; Monecke S; Ehricht R; Slickers P; Thomas JC; Appleton S; Goering RV; Robinson DA; Coombs GW
    Clin Microbiol Infect; 2015 May; 21(5):444-50. PubMed ID: 25708549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program.
    Biedenbach DJ; Hoban DJ; Reiszner E; Lahiri SD; Alm RA; Sahm DF; Bouchillon SK; Ambler JE
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7873-7. PubMed ID: 26416860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of EUCAST, CLSI and USCAST ceftaroline breakpoint changes on the susceptibility of methicillin-resistant Staphylococcus aureus isolates collected from US medical centres (2015-2018).
    Sader HS; Jones RN
    Clin Microbiol Infect; 2020 May; 26(5):658-659. PubMed ID: 31899333
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.